🇦🇪 Hu3F8 in United Arab Emirates

Hu3F8 (NAXITAMAB) regulatory status in United Arab Emirates.

Marketing authorisation

MOH

  • Status: likely_approved

Hu3F8 in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Oncology approved in United Arab Emirates

Frequently asked questions

Is Hu3F8 approved in United Arab Emirates?

Yes. MOH has authorised it.

Who is the marketing authorisation holder for Hu3F8 in United Arab Emirates?

Y-Mabs Therapeutics Inc is the originator. The local marketing authorisation holder may differ — check the official source linked above.